Departamento de Bioquímica, Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México, Mexico.
Departamento de Biomedicina Cardiovascular, Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México, Mexico.
Arch Pharm (Weinheim). 2024 Nov;357(11):e2400492. doi: 10.1002/ardp.202400492. Epub 2024 Jul 29.
Drug repurposing is defined as the use of approved therapeutic drugs for indications different from those for which they were originally designed. Repositioning diminishes both the time and cost for drug development by omitting the discovery stage, the analysis of absorption, distribution, metabolism, and excretion routes, as well as the studies of the biochemical and physiological effects of a new compound. Besides, drug repurposing takes advantage of the increased bioinformatics knowledge and availability of big data biology. There are many examples of drugs with repurposed indications evaluated in in vitro studies, and in pharmacological, preclinical, or retrospective clinical analyses. Here, we briefly review some of the experimental strategies and technical advances that may improve translational research in cardiovascular diseases. We also describe exhaustive research from basic science to clinical studies that culminated in the final approval of new drugs and provide examples of successful drug repurposing in the field of cardiology.
药物再利用是指将已批准的治疗药物用于与其最初设计目的不同的适应症。重新定位通过省略发现阶段、吸收、分布、代谢和排泄途径的分析以及新化合物的生化和生理作用的研究，缩短了药物开发的时间和成本。此外，药物再利用还利用了日益增长的生物信息学知识和大数据生物学的可用性。有许多具有重新定位适应症的药物的例子在体外研究中进行了评估，以及在药理学、临床前或回顾性临床分析中进行了评估。在这里，我们简要回顾了一些可能改善心血管疾病转化研究的实验策略和技术进展。我们还描述了从基础科学到临床研究的详尽研究，最终导致新药的最终批准，并提供了心脏病学领域成功药物再利用的例子。
